As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to “focus on names with …
Curis, Inc. (Nasdaq:CRIS), announced the pricing of an underwritten registered public offering of 21,818,181 shares of its common stock at a public offering price …
Curis, Inc. (NASDAQ:CRIS), announced that it has commenced an underwritten public offering of shares of its common stock.
In a research report sent to investors, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Curis Inc. (NASDAQ:CRIS) with a $6.
Curis Inc. (NASDAQ:CRIS) announced a collaboration, license and option agreement with Aurigene focused on the development of small molecule inhibitors of immuno-oncology and …
In a research report sent to investors, Cowen analyst Boris Peaker reiterated an Outperform rating on Curis Inc. (NASDAQ:CRIS), following the news that …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Curis Inc. (NASDAQ:CRIS) with a price target of $10, as the company announced dosing …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Curis Inc. (NASDAQ:CRIS) with a price target …
In a research report published yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Curis Inc. (NASDAQ:CRIS) with a $10 price target, as …
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a “Buy” rating on Curis Inc. (CRIS), and a price target of $10.
